PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 December; 7(4): E54–E62.
Published online 2014 March 30. doi:  10.1208/pt070490
PMCID: PMC2750327

Evaluation of porous carrier-based floating orlistat microspheres for gastric delivery

Abstract

The purpose of this research was to prepare floating microspheres consisting of (1) calcium silicate as porous carrier; (2) orlistat, an oral anti-obesity agent; and (3) Eudragit S as polymer, by solvent evaporation method and to evaluate their gastro-retentive and controlled-release properties. The effect of various formulation and process variables on the particle morphology, micromeritic properties, in vitro floating behavior, percentage drug entrapment, and in vitro drug release was studied. The gamma scintigraphy of the optimized formulation was performed in albino rabbits to monitor the transit of floating microspheres in the gastrointestinal tract. The orlistat-loaded optimized formulation was orally administered to albino rabbits, and blood samples collected were used to determine pharmacokinetic parameters of orlistat from floating microspheres. The microspheres were found to be regular in sphae and highly porous. Microsphere formulation CS4, containing 200 mg calcium silicate, showed the best floating ability (88%±4% buoyancy) in simulated gastric fluid as compared with other formulations. Release pattern of orlistat in simulated gastric fluid from all floating microspheres followed Higuchi matrix model and Peppas-Korsmeyer model. Prolonged gastric residence time of over 6 hours was achieved in all rabbits for calcium silicate-based floating microspheres of orlistat. The enhanced elimination half-life observed after pharmacokinetic investigations in the present study is due to the floating nature of the designed formulations.

Keywords: Orlistat, calcium silicate, floating drug delivery, microspheres, gamma scintigraphy, pharmacokinetic study

Full Text

The Full Text of this article is available as a PDF (587K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Singh BM, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235–259. doi: 10.1016/S0168-3659(99)00204-7. [PubMed] [Cross Ref]
2. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of cimetidine: formulation, characterization and in vitro evaluation. Acta Pharm. 2005;55:277–285. [PubMed]
3. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. Physicochemical properties to determine the buoyancy of hollow microspheres (microballons) prepared by the emulsion solvent diffusion method. Eur J Pharm Biopharm. 2003;55:297–304. doi: 10.1016/S0939-6411(03)00003-1. [PubMed] [Cross Ref]
4. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. In vivo evaluation of riboflavin containing microballons for floating controlled drug delivery system in healthy human volunteers. J Control Release. 2003;93:39–47. doi: 10.1016/S0168-3659(03)00370-5. [PubMed] [Cross Ref]
5. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm. 2002;241:279–292. doi: 10.1016/S0378-5173(02)00241-7. [PubMed] [Cross Ref]
6. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastro-retentive floating drug delivery: preparation and in vitro characterization. J Control Release. 2005;107:300–309. doi: 10.1016/j.jconrel.2005.06.007. [PubMed] [Cross Ref]
7. Jain SK, Agrawal GP, Jain NK. A novel calcium silicate based microspheres of repaglinide: in vivo investigations. J Control Release. 2006;113:111–116. doi: 10.1016/j.jconrel.2006.04.005. [PubMed] [Cross Ref]
8. Jain AK, Jain SK, Yadav A, Agrawal GP. Controlled release calcium silicate based floating granular delivery system of ranitidine hydrochloride. Curr Drug Deliv. 2006; In press. [PubMed]
9. Keating GM, Jarvis B. Orlistat. Drugs. 2001;61:2107–2119. doi: 10.2165/00003495-200161140-00011. [PubMed] [Cross Ref]
10. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. I. Application of calcium silicate as a floating carrier. Chem Pharm Bull (Tokyo) 1996;44:1361–1366. doi: 10.1248/cpb.44.1361. [Cross Ref]
11. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci. 1992;81:135–140. doi: 10.1002/jps.2600810207. [PubMed] [Cross Ref]
12. Choi HK, Lee JH, Park TG. Effect of formulation and processing variables on the characteristics of microspheres for water-soluble drugs prepared by w/o/o double emulsion solvent diffusion method. Int J Pharm. 2000;196:75–83. doi: 10.1016/S0378-5173(99)00440-8. [PubMed] [Cross Ref]
13. Martin A, editor. Physical Pharmacy. 4th ed. Philadelphia, PA: Lea Febiger; 1993. pp. 431–432.
14. Bennett PK, Li YT, Edom R, Henion J. Quantitative determination of Orlistat (tetrahydrolipostatin, Ro 18-0647) in human plasma by high-performance liquid chromatography coupled with ion spray tandem mass spectrometry. J Mass Spectrom. 1997;32:739–749. doi: 10.1002/(SICI)1096-9888(199707)32:7<739::AID-JMS526>3.0.CO;2-C. [PubMed] [Cross Ref]
15. Wieboldt R, Campbell DA, Henion J. Quantitative liquid chromatographic-tandem mass spectrometric determination of orlistat in plasma with a quadrupole ion trap. J Chromatogr B Biomed Sci Appl. 1998;708:121–129. doi: 10.1016/S0378-4347(97)00653-1. [PubMed] [Cross Ref]
16. Polli JE, Rehki GS, Augsburger LL, Shah VP. Methods to compare dissolution profiles and a rationale for wide dissolution specification for metoprolol tartrate tablets. J Pharm Sci. 1997;86:690–700. doi: 10.1021/js960473x. [PubMed] [Cross Ref]
17. Wu PC, Tsai MJ, Huang YB, Cheng JS, Tsai YH. In vitro and in vivo evaluation of potassium chloride sustained release formulation prepared with saturated polyglycolyed glycerides matrices. Int J Pharm. 2002;243:119–124. doi: 10.1016/S0378-5173(02)00264-8. [PubMed] [Cross Ref]
18. Atyabi F, Sharma HL, Mohammad HAH, Fell JT. In vivo evaluation of a novel gastro-retentive formulation based on ion exchange resins. J Control Release. 1996;42:105–113. doi: 10.1016/0168-3659(96)01344-2. [Cross Ref]
19. El-Kamel AH, Sokar MS, Al-Gamal SS, Naggar VF. Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharm. 2001;220:13–21. doi: 10.1016/S0378-5173(01)00574-9. [PubMed] [Cross Ref]
20. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res. 1993;10:1321–1325. doi: 10.1023/A:1018921830385. [PubMed] [Cross Ref]
21. Khattar D, Ahuja A, Khar RK. Hydrodynamically balanced systems as sustained release dosage forms for propranolol hydrochloride. Pharmazie. 1990;45:356–358. [PubMed]
22. Saha GB, editor. Radiolabeling of Compounds. New York, NY: Springer-Verlag; 1979. pp. 86–91.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists